NAMS
NewAmsterdam Pharma Company N.V.
22.10$
-0.6%
vs. previous close
Closing price · As of: Oct 7, 2026
Statements
Cash Flow
NewAmsterdam Pharma Company N.V. (NAMS) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Operating Cash Flow" came in at -39 million USD. Tick rows to compare them in a chart.
All figures in millions of USD.
Tick rows to compare them in a chart (up to 4)
| Line item | Q1 20 | Q2 20 | Q3 20 | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -1.5 | -1.5 | -1.5 | -1.5 | -0.2 | -0.4 | -0.2 | 0.6 | -0.4 | -0.2 | -0.2 | 27 | -32 | -29 | -35 | -33 | -55 | -54 | -13 | -37 | -36 | -38 | -33 | -41 | -31 | -39 | -143 | |
| 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.2 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 | 0.1 | 0.0 | 0.1 | 0.1 | 0.1 | 0.1 | 0.2 | |
| – | – | – | – | 0.3 | 0.3 | 0.3 | 0.3 | – | – | – | 1.9 | 7.6 | 5.6 | 5.6 | 6.0 | 7.9 | 8.3 | 8.0 | 9.4 | 15 | 15 | 15 | 14 | 18 | 18 | 65 | |
| – | – | – | – | -0.3 | -0.3 | – | – | -0.4 | -0.4 | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| -0.1 | -0.1 | -0.1 | -0.1 | 0.0 | -0.1 | 0.2 | 0.0 | 0.0 | 1.8 | 2.1 | 53 | -0.6 | 3.0 | 2.6 | 9.3 | -10 | -15 | 0.0 | -8.0 | 10 | -24 | -10 | 4.6 | 4.1 | 1.4 | -0.2 | |
| 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.4 | 0.2 | 0.1 | 0.0 | 0.0 | 0.1 | 0.0 | 0.1 | 0.0 | 0.1 | 0.3 | |
| 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -0.1 | -0.1 | – | 0.0 | -2.6 | 0.0 | -0.4 | -0.2 | -0.1 | -62 | 2.9 | -159 | 2.5 | -21 | -12 | -4.8 | -35 | |
| – | – | – | – | 0.0 | 0.0 | – | – | 0.0 | 0.0 | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| 2.8 | 2.8 | 2.8 | 2.8 | 40 | 41 | 0.0 | 6.2 | 0.0 | 42 | 157 | 157 | 2.4 | 6.3 | 0.2 | 0.0 | 198 | 4.7 | 0.1 | 457 | 6.5 | 3.4 | 5.9 | 14 | 11 | 11 | 42 | |
| 1.3 | 1.3 | 1.3 | 1.3 | -0.2 | -0.4 | -0.2 | 0.6 | -0.4 | -0.2 | -0.2 | 468 | -26 | -25 | -33 | -28 | 141 | -50 | -8.0 | 349 | -23 | -185 | -24 | -48 | -32 | -33 | -138 | |
| -1.5 | -1.5 | -1.5 | -1.5 | -0.2 | -0.4 | -0.2 | 0.6 | -0.4 | -0.2 | -0.2 | 29 | -32 | -29 | -35 | -33 | -55 | -54 | -13 | -37 | -36 | -38 | -33 | -41 | -31 | -39 | -144 |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 7, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.